<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03294304</url>
  </required_header>
  <id_info>
    <org_study_id>2017LS039</org_study_id>
    <nct_id>NCT03294304</nct_id>
  </id_info>
  <brief_title>BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy</brief_title>
  <official_title>BLASST-1 (Bladder Cancer Signal Seeking Trial): Phase II Trial of Neoadjuvant Nivolumab With Cisplatin and Gemcitabine in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Radical Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center Phase II study to determine the safety and efficacy of nivolumab when&#xD;
      given in combination with cisplatin and gemcitabine as neoadjuvant treatment in patients with&#xD;
      muscle-invasive bladder cancer (MIBC) prior to standard of care radical cystectomy. Patients&#xD;
      will receive neoadjuvant treatment with nivolumab in combination with gemcitabine-cisplatin&#xD;
      (GC) every 3 weeks for 4 treatment cycles over 12 weeks followed by standard of care radical&#xD;
      cystectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Response Rate (PaR) at time of radical cystectomy. PaR is defined as absence of residual MIBC at cystectomy in the surgical specimen (pathologic down-staging to ≤pT1pN0, which includes pT0, pT1,pTa and pTis)</measure>
    <time_frame>Surgery Day 1</time_frame>
    <description>Incidence of Measurable Disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 1)</measure>
    <time_frame>Day 8</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 2)</measure>
    <time_frame>Day 1</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 2)</measure>
    <time_frame>Day 8</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 3)</measure>
    <time_frame>Day 1</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 3)</measure>
    <time_frame>Day 8</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 4)</measure>
    <time_frame>Day 1</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 4)</measure>
    <time_frame>Day 8</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Nivolumab with Gemcitabine/Cisplatin</measure>
    <time_frame>30 Days +/- 7 Days after last chemotherapy</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Nivolumab with Gemcitabine/Cisplatin</measure>
    <time_frame>4 weeks post radical cystectomy</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Every 3 Months for 2 Years</time_frame>
    <description>Incidence of PFS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab, Cisplatin, &amp; Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.</description>
    <arm_group_label>Nivolumab, Cisplatin, &amp; Gemcitabine</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.</description>
    <arm_group_label>Nivolumab, Cisplatin, &amp; Gemcitabine</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.</description>
    <arm_group_label>Nivolumab, Cisplatin, &amp; Gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of MIBC (predominantly urothelial carcinoma) with clinical stage T2-T4a and&#xD;
             N&lt;1 disease (solitary lymph node measuring &lt; 2 cm) and M0 and deemed eligible for&#xD;
             radical cystectomy.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1.&#xD;
&#xD;
          -  Required initial laboratory values within 14 days of study enrollment:&#xD;
&#xD;
               -  Absolute Neutrophil Count ≥ 1500 cells/mm^3&#xD;
&#xD;
               -  Platelets ≥ 100,000 cells/mm^3&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 times the upper limit of normal (ULN) for the institution (For&#xD;
                  patients with known Gilbert's disease: bilirubin ≤ 3 x ULN)&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN for the&#xD;
                  institution&#xD;
&#xD;
               -  Creatinine clearance ≥ 50 ml/min by Cockcroft-Gault formula or 24 hour urinary&#xD;
                  clearance (CrCl = [140-age (years)] x actual weight (kg) / [72 x serum Cr&#xD;
                  (mg/dL)] (if patient is female multiply the above by 0.85) or 24 hour urinary&#xD;
                  creatinine clearance.&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 x ULN for the institution&#xD;
&#xD;
               -  INR and aPTT ≤ 1.5 x ULN if not on therapeutic anticoagulation. Patients&#xD;
                  receiving therapeutic anticoagulation will be allowed if maintained on a stable&#xD;
                  dose.&#xD;
&#xD;
          -  Females of childbearing potential and males who are not surgically sterile and with&#xD;
             partners of childbearing potential must agree to use effective contraception during&#xD;
             study treatment for 5 months for females and 7 months for males after the last dose of&#xD;
             nivolumab.&#xD;
&#xD;
          -  Ability to provide a signed and dated consent or have a legally authorized&#xD;
             representative to provide written and signed consent prior to the initiation of any&#xD;
             research related procedures.&#xD;
&#xD;
          -  Patient must agree to submission of archived tumor (20-25 formalin-fixed paraffin&#xD;
             embedded (FFPE) slides of 5-10 microns in thickness) from TURBT and radical cystectomy&#xD;
             tissues. If archived samples are not available fresh tissue will be used.&#xD;
&#xD;
          -  Ability to provide written consent prior to the initiation of any research related&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of N2-3 or M1 disease.&#xD;
&#xD;
          -  Ineligible to receive cisplatin by meeting one or more of the following criteria;&#xD;
&#xD;
               -  Creatinine clearance of &lt; 50 mL/min&#xD;
&#xD;
               -  Hearing loss of 25 dB at two contiguous frequencies with testing required if a&#xD;
                  patient has hearing loss - At the investigator's discretion, and after discussion&#xD;
                  with the patient, this exclusion may be waived if the potential benefit of&#xD;
                  cisplatin therapy is felt to outweigh the risk of further hearing loss.&#xD;
&#xD;
               -  CTCAE v4 Grade 2 or higher peripheral neuropathy,&#xD;
&#xD;
               -  New York Heart Association Class III or IV heart failure&#xD;
&#xD;
               -  ECOG performance status 2 or higher.&#xD;
&#xD;
          -  Prior systemic therapy (intravenous) is not permitted. Prior intravesical therapies&#xD;
             including intravesical gemcitabine is permitted for non-muscle invasive disease (i.e.&#xD;
             T1 or lower).&#xD;
&#xD;
          -  Prior treatment with cisplatin for bladder cancer.&#xD;
&#xD;
          -  Prior treatment with anti-PD-1, CTLA-4, or anti-PD-L1 therapeutic antibody or&#xD;
             pathway-targeting agents.&#xD;
&#xD;
          -  Prior therapeutic radiation to the bladder.&#xD;
&#xD;
          -  Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of&#xD;
             need for a major surgical procedure during the course of the study.&#xD;
&#xD;
          -  Any of the following within the 6 months prior to study drug administration:&#xD;
             myocardial infarction, severe/unstable angina, symptomatic congestive heart failure&#xD;
             (&gt;New York Heart Association Class 2), stroke, serious cardiac arrhythmia.&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome&#xD;
             (AIDS)-related illness.&#xD;
&#xD;
          -  Pregnancy, lactation, or breast-feeding. Women of childbearing potential must have a&#xD;
             negative urine pregnancy test at screening.&#xD;
&#xD;
          -  History of autoimmune disease, including but not limited to myasthenia gravis,&#xD;
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,&#xD;
             inflammatory bowel disease, Wegener's granulomatosis, vascular thrombosis associated&#xD;
             with antiphospholipid syndrome, Sjogren's syndrome, Guillain-Barre syndrome, multiple&#xD;
             sclerosis, systemic vasculitis, or glomerulonephritis.&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),&#xD;
             organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing&#xD;
             pneumonia, etc.), or evidence of active pneumonitis on screening chest computed&#xD;
             tomography (CT) scan, history of radiation pneumonitis in the radiation field&#xD;
             (fibrosis) is permitted.&#xD;
&#xD;
          -  Active hepatitis B virus (HBV, chronic or acute, defined as having a positive&#xD;
             hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C antibody.&#xD;
             Patients with past HBV infection or resolved HBV infection (defined as the presence of&#xD;
             hepatitis B core antibody [HBc Ab] and absence of HBsAg) are eligible. HBV DNA must be&#xD;
             obtained in these patients prior to Cycle 1, Day 1 and confirmed to be negative.&#xD;
             Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase&#xD;
             chain reaction is negative for HCV RNA.&#xD;
&#xD;
          -  Active tuberculosis or BCG infection&#xD;
&#xD;
          -  Active infection requiring systemic antibiotics for more than 7 days within 3 days&#xD;
             prior to Cycle 1, Day 1. Prophylactic short-term antibiotics will be allowed.&#xD;
&#xD;
          -  Administration of intravesical bacillus Calmette-Guerin (BCG) within 4 weeks before&#xD;
             Cycle 1, Day 1&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or&#xD;
             anticipation that such a live attenuated vaccine will be required during the study.&#xD;
&#xD;
          -  Persisting toxicity from prior therapy (NCI CTCAE v4.03 Grade &gt;1); however alopecia or&#xD;
             other Grade &lt;2 AEs not constituting a safety risk, based on Investigator's judgement,&#xD;
             are acceptable.&#xD;
&#xD;
          -  History of or active bone marrow disorders expected to interfere with study therapy&#xD;
             (e.g. acute leukemias, accelerated/blast-phase chronic myelogenous leukemia, chronic&#xD;
             lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory&#xD;
             myeloma).&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplant.&#xD;
&#xD;
          -  Known primary central nervous system (CNS) malignancy.&#xD;
&#xD;
          -  Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with&#xD;
             dermatologic manifestations only (e.g., patients with psoriatic arthritis would be&#xD;
             excluded) are permitted but patients with psoriasis require a baseline ophthalmologic&#xD;
             exam to rule out ocular manifestations. Rash must cover less than 10% of body surface&#xD;
             area (BSA) and must be well controlled at baseline and only requiring topical&#xD;
             steroids.&#xD;
&#xD;
          -  Any other chronic medical condition or psychiatric condition, physical examination&#xD;
             finding, or clinical laboratory finding giving reasonable suspicion of a disease or&#xD;
             condition that contraindicates the use of an investigational drug or that may affect&#xD;
             the interpretation of the results or render the patient at high risk from treatment&#xD;
             complications&#xD;
&#xD;
          -  Known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin or in situ cervical cancer that has undergone potentially curative therapy.&#xD;
             Patients on androgen deprivation therapy as part of adjuvant therapy after radiation&#xD;
             for prostate cancer or patients on adjuvant hormonal therapies for breast cancer will&#xD;
             be allowed if they are being considered for curative intent for bladder cancer.&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents (including but not limited to&#xD;
             interferon [IFN]-a or interleukin [IL]-2) within 4 weeks or five half-lives of the&#xD;
             drug (whichever is shorter) prior to Cycle 1, Day 1&#xD;
&#xD;
          -  Concomitant use of systemic corticosteroids at physiologic doses or &lt;10 mg/day of&#xD;
             prednisone or equivalent.&#xD;
&#xD;
          -  Concomitant use of another investigational agent and/or treatment with an&#xD;
             investigational agent within 4 weeks prior to Cycle 1, Day 1 (or within five halflives&#xD;
             of the investigational product, whichever is longer).&#xD;
&#xD;
          -  Use of bisphosphonate therapy for osteoporosis will be allowed if started prior to&#xD;
             study enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Badrinath Konety, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shilpa Gupta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center - University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute - University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MIBC</keyword>
  <keyword>UC</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT03294304/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>June 3, 2021</submitted>
    <returned>June 24, 2021</returned>
    <submitted>November 18, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

